卡麦角林联合取卵后GnRH拮抗剂给药预防卵巢过度刺激综合征
回顾性队列研究纳入2011至2018年480例有OHSS风险且采用GnRH激动剂扳机的IVF患者,分为单用扳机组208例、扳机加卡麦角林组167例、扳机加卡麦角林加GnRH拮抗剂组105例。结果显示加用卡麦角林及后续黄体期加用GnRH拮抗剂5天可依次降低轻中度OHSS风险并改善患者舒适度,无重度OHSS发生。
要点
- 单用GnRH激动剂扳机组轻中度OHSS发生率为38%,高于加用卡麦角林组的29%和再加用GnRH拮抗剂组的18%。
- 加用卡麦角林组轻中度OHSS发生率29%高于加用GnRH拮抗剂组的18%,差异有统计学意义。
- 三组均无重度OHSS发生,联合方案可改善腹部不适和腹胀等症状。
核心结论
- 在高OHSS风险患者中,GnRH激动剂扳机后加用卡麦角林、并在黄体期后续加用GnRH拮抗剂5天,可依次降低轻中度OHSS风险并改善患者舒适度。
研究设计与样本
- 回顾性队列研究,纳入2011至2018年480例有OHSS风险且采用GnRH激动剂扳机的IVF患者。
- 按治疗分为三组:GnRH激动剂扳机单用组208例、扳机加卡麦角林组167例、扳机加卡麦角林加GnRH拮抗剂组105例。
主要发现
- 单用扳机组游离腹腔积液发生率28%,高于加用卡麦角林组的19%(P=0.04)和再加用GnRH拮抗剂组的5%(P=0.001)。
- 单用扳机组腹部不适和腹胀发生率33%,高于加用卡麦角林组的21%(P=0.01)和再加用GnRH拮抗剂组的18%(P=0.006)。
- 电解质异常单用扳机组多于加用卡麦角林组,加用卡麦角林组多于再加用GnRH拮抗剂组。
- 轻中度OHSS发生率单用扳机组38%,高于加用卡麦角林组的29%(P=0.048)和再加用GnRH拮抗剂组的18%(P=0.006),加用卡麦角林组高于再加用GnRH拮抗剂组(P=0.046)。
- 无患者发生重度OHSS。
临床怎么用
- 作者认为,对高OHSS风险患者采用GnRH激动剂扳机后加用卡麦角林,并在黄体期后续加用GnRH拮抗剂5天,可依次降低轻中度OHSS风险并改善患者舒适度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does the addition of a gonadotrophin-releasing hormone (GnRH) antagonist to cabergoline treatment during the luteal phase in fresh IVF cycles triggered with a GnRH agonist, and planned for freeze-all, reduce the rate of mild and moderate ovarian hyperstimulation syndrome (OHSS)? DESIGN: Retrospective cohort study of 480 IVF patients at risk for OHSS with GnRH agonist trigger from 2011 to 2018, stratified into three groups based on treatment received: GnRH agonist trigger alone (Group 1, n = 208), GnRH agonist trigger + cabergoline (Group 2, n = 167) or GnRH agonist trigger + cabergoline + GnRH antagonist (Group 3, n = 105). Data on patient demographics, incidence, severity and symptomatology of OHSS and laboratory findings were collected. RESULTS: Group 1 had more free peritoneal fluid than Group 2 (28% versus 19%, P = 0.04) or Group 3 (28% versus 5%, P = 0.001). Group 1 reported abdominal discomfort and bloating more than Group 2 (33% versus 21%, P = 0.01) or Group 3 (33% versus 18%, P = 0.006). Group 1 had more electrolyte abnormalities than Group 2, who had more than Group 3. No patients developed severe OHSS. Mild and moderate OHSS rate was higher in Group 1 (38%) than Group 2 (29%, P = 0.048) or Group 3 (18%, P = 0.006) and in Group 2 than Group 3 (P = 0.046). CONCLUSION: Addition of cabergoline to GnRH agonist triggering in high-risk OHSS patients, and subsequent addition of GnRH antagonist for 5 days in the luteal phase, sequentially reduces the risk of mild and moderate OHSS and improves patient comfort compared with GnRH agonist trigger alone.
引用
- Shrem G, Steiner N, Balayla J, et al. Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2019. PMID: 31320288. doi:10.1016/j.rbmo.2019.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。